Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company focuses primarily on antiviral therapies, particularly for HIV/AIDS, hepatitis B and C, and COVID-19, as well as oncology and inflammation. Gilead's portfolio includes blockbuster drugs such as Biktarvy, Truvada, and Veklury (remdesivir). The company operates globally, with headquarters in Foster City, California.

Gilead's business model centers on research and development of proprietary drugs, which it markets and sells directly to healthcare providers, hospitals, and government agencies. Revenue is predominantly generated from its HIV franchise, which accounts for over 60% of total sales, followed by liver disease treatments and oncology. The company also earns royalties and licensing fees from partnerships. Gilead's high gross margin of 78.83% reflects the pricing power of its patented drugs.

Gilead operates in the highly competitive pharmaceutical industry, specifically in antiviral and oncology markets. Key competitors include AbbVie, Merck, Johnson & Johnson, and Bristol Myers Squibb. Gilead's competitive advantage lies in its strong HIV portfolio and its leadership in antiviral research. The company's profit margin of 30.99% and operating margin of 39.74% indicate efficient operations, while its EV/EBITDA of 12.15 suggests a reasonable valuation relative to earnings.

Gilead's primary customers are healthcare professionals, hospitals, clinics, and government health programs. Its main geographic markets are the United States (around 60% of revenue), Europe, and Asia. The company's therapies target patients with chronic viral infections and cancers. With a dividend yield of 2.51% and a free cash flow yield of 6.13%, Gilead offers income potential alongside growth from its pipeline.

An auto-generated descriptive profile based on company data, for informational purposes only.